Revolution Medicines
RVMD
117 hedge funds and large institutions have $1.85B invested in Revolution Medicines in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 40 increasing their positions, 29 reducing their positions, and 15 closing their positions.
79% more call options, than puts
Call options by funds: $2.28M | Put options by funds: $1.27M
38% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 29
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
3% more funds holding
Funds holding: 114 → 117 (+3)
1.25% more ownership
Funds ownership: 98.26% → 99.51% (+1.3%)
7% less capital invested
Capital invested by funds: $1.99B → $1.85B (-$144M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$58.1M |
| 2 |
BlackRock
New York
|
+$10.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$7.62M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.31M |
| 5 |
Citigroup
New York
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$47.8M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$20.1M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$19M |
| 4 |
DM
Deerfield Management
New York
|
-$19M |
| 5 |
CC
Casdin Capital
New York
|
-$12.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Simplex Trading
Chicago,
Illinois
| – | -$30.2K | -1,070 | Closed |
|
|
AF
127
Allworth Financial
Folsom,
California
| – | -$3K | -100 | Closed |
|
|
S
128
SignatureFD
Atlanta,
Georgia
| – | -$1K | -26 | Closed |
|
|
SOW
129
State of Wyoming
Cheyenne,
Wyoming
| – | -$28 | -1 | -8% |
|
130
Osaic Holdings
Scottsdale,
Arizona
| – | +$254 | +9 | New |
|
|
C
131
Covestor
London,
United Kingdom
| – | +$479 | +17 | New |
|
RVMD Hedge Fund Activity: Q4 2021 in Review
117 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q4 2021, worth a combined $1.85B — down 7.2% from $1.99B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new RVMD positions and 15 closed out — a net gain of 4 holders — while 40 added to existing stakes and 29 trimmed.
The largest buyer was Woodline Partners, adding an estimated $58.1M. The largest seller was Fidelity Investments, cutting an estimated $47.8M.
- 117 institutional investors held Revolution Medicines (RVMD) as of Q4 2021, up from 114 in Q3 2021.
- Funds reported $1.85B of Revolution Medicines stock for Q4 2021, down 7.2% quarter-over-quarter.
- 19 funds opened new Revolution Medicines positions in Q4 2021 and 15 closed out, a net change of +4 holders.
- The largest Revolution Medicines buyer in Q4 2021 was Woodline Partners, an estimated $58.1M added.
- The largest Revolution Medicines seller in Q4 2021 was Fidelity Investments, an estimated $47.8M sold.
Based on aggregated 13F filings for Q4 2021.